Stay updated with breaking news from Neil Kumar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BridgeBio Pharma (NASDAQ:BBIO – Get Rating) posted its quarterly earnings results on Thursday. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09), Briefing.com reports. The business had revenue of $1.83 million during the quarter, compared to analysts’ expectations of $3.23 million. During the same quarter […]
BridgeBio Pharma (NASDAQ:BBIO – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09), Briefing.com reports. The business had revenue of $1.83 million for the quarter, compared to the consensus estimate of $3.23 million. The company’s revenue was […]
Fernwood Investment Management LLC trimmed its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) by 0.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 203,000 shares of the company’s stock after selling 1,550 shares during the period. […]
Pinnacle Wealth Management Advisory Group LLC reduced its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) by 6.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 43,500 shares of the company’s stock after selling 3,237 shares during the period. Pinnacle Wealth Management Advisory […]
BridgeBio Pharma (NASDAQ:BBIO – Get Rating) and Oncorus (NASDAQ:ONCR – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability. Risk and Volatility BridgeBio Pharma has a beta of 0.71, indicating […]